Request Free Sample ×
Radiopharmaceutical Synthesizer Market Research Report - Forecast 2035 Infographic

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

Radiopharmaceutical Synthesizer Market

ID: MRFR/Pharma/25982-HCR
100 Pages
Rahul Gotadki
March 2026

Radiopharmaceutical Synthesizer Market Research Report By Modality (PET, SPECT, Others), By Application (Oncology, Cardiology, Neurology, Others), By Radioisotope (Fluorine-18, Carbon-11, Gallium-68, Others), By Synthesis Method (Solid-Phase, Liquid-Phase, Gas-Phase, Others) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Radiopharmaceutical Synthesizer Market Infographic
Purchase Options
Compare License
Summary Table of Contents Segmentation Methodology Download PDF

Radiopharmaceutical Synthesizer Market Summary

As per Market Research Future analysis, the Radiopharmaceutical Synthesizer Market Size was estimated at 3.108 USD Billion in 2024. The Radiopharmaceutical Synthesizer industry is projected to grow from 3.246 USD Billion in 2025 to 5.002 USD Billion by 2035, exhibiting a compound annual growth rate (CAGR) of 4.42%

Key Market Trends & Highlights

The Radiopharmaceutical Synthesizer Market is poised for substantial growth driven by technological advancements and increasing demand for personalized medicine.

  • Technological advancements in radiopharmaceutical synthesizers are enhancing the efficiency and accuracy of diagnostic imaging.
  • North America remains the largest market, while the Asia-Pacific region is emerging as the fastest-growing area for radiopharmaceutical synthesizers.
  • The PET segment continues to dominate the market, whereas the SPECT segment is experiencing rapid growth due to its applications in various medical fields.
  • The rising incidence of cancer and other diseases, coupled with advancements in radiopharmaceutical technologies, are key drivers propelling market expansion.

Market Size & Forecast

2024 Market Size 3.108 (USD Billion)
2035 Market Size 5.002 (USD Billion)
CAGR (2025 - 2035) 4.42%

Major Players

GE Healthcare (US), Siemens Healthineers (DE), Philips Healthcare (NL), Elekta (SE), Bracco Imaging (IT), Lantheus Medical Imaging (US), NorthStar Medical Radioisotopes (US), Radiopharma (FR), IThemba LABS (ZA)

Our Impact
Enabled $4.3B Revenue Impact for Fortune 500 and Leading Multinationals
Partnering with 2000+ Global Organizations Each Year
30K+ Citations by Top-Tier Firms in the Industry

Radiopharmaceutical Synthesizer Market Trends

The Radiopharmaceutical Synthesizer Market is currently experiencing a notable evolution, driven by advancements in technology and increasing demand for precise diagnostic tools. The integration of automation and artificial intelligence into synthesizer systems appears to enhance efficiency and accuracy in the production of radiopharmaceuticals. This trend is likely to facilitate the development of personalized medicine, as healthcare providers seek tailored treatment options for patients. Furthermore, the growing prevalence of chronic diseases necessitates improved imaging techniques, which may further propel the market forward. In addition, regulatory bodies are increasingly focusing on the safety and efficacy of radiopharmaceuticals, which could lead to more stringent guidelines for synthesizer manufacturers. This regulatory landscape may encourage innovation, as companies strive to meet compliance requirements while also addressing the needs of healthcare professionals. The Radiopharmaceutical Synthesizer Market seems poised for growth, with potential opportunities arising from collaborations between technology firms and healthcare institutions. As the market continues to evolve, stakeholders must remain vigilant to emerging trends and adapt their strategies accordingly.

Technological Advancements

The Radiopharmaceutical Synthesizer Market is witnessing a surge in technological innovations, particularly in automation and artificial intelligence. These advancements are likely to streamline production processes, enhance precision, and reduce human error, thereby improving overall efficiency.

Regulatory Compliance

As regulatory agencies intensify their scrutiny of radiopharmaceuticals, manufacturers are compelled to adapt to evolving compliance standards. This trend may drive innovation, as companies seek to develop synthesizers that not only meet safety requirements but also enhance product quality.

Personalized Medicine

The increasing focus on personalized medicine is shaping the Radiopharmaceutical Synthesizer Market. As healthcare providers aim to deliver tailored treatments, the demand for specific radiopharmaceuticals is expected to rise, prompting synthesizer manufacturers to innovate and diversify their offerings.

Radiopharmaceutical Synthesizer Market Drivers

Growing Focus on Personalized Medicine

The increasing emphasis on personalized medicine is influencing the Radiopharmaceutical Synthesizer Market significantly. As healthcare shifts towards tailored treatment approaches, the demand for specific radiopharmaceuticals that cater to individual patient profiles is on the rise. This trend necessitates the development of synthesizers capable of producing customized radiopharmaceuticals efficiently. The market is likely to see a surge in demand for synthesizers that can quickly adapt to varying production requirements, thereby supporting the growing need for personalized diagnostic and therapeutic solutions. This shift towards personalized medicine is expected to create new opportunities for market players.

Increasing Demand for Diagnostic Imaging

The rising demand for diagnostic imaging techniques, such as positron emission tomography (PET) and single-photon emission computed tomography (SPECT), is a primary driver for the Radiopharmaceutical Synthesizer Market. As healthcare providers increasingly rely on these imaging modalities for accurate diagnosis and treatment planning, the need for efficient and reliable radiopharmaceutical synthesizers becomes paramount. The market for diagnostic imaging is projected to grow significantly, with estimates suggesting a compound annual growth rate (CAGR) of over 6% in the coming years. This growth is likely to spur investments in advanced synthesizer technologies, enhancing the capabilities of radiopharmaceuticals in clinical settings.

Regulatory Support and Funding Initiatives

Regulatory bodies are increasingly supporting the development and commercialization of radiopharmaceuticals, which is beneficial for the Radiopharmaceutical Synthesizer Market. Initiatives aimed at expediting the approval processes for new radiopharmaceuticals and providing funding for research and development are likely to stimulate market growth. Governments and health organizations are recognizing the potential of radiopharmaceuticals in improving patient care, leading to increased investments in this sector. Such regulatory support not only enhances the market landscape but also encourages innovation among manufacturers, fostering a competitive environment that could lead to the introduction of advanced synthesizer technologies.

Rising Incidence of Cancer and Other Diseases

The escalating incidence of cancer and other chronic diseases is a critical driver for the Radiopharmaceutical Synthesizer Market. As the prevalence of these conditions continues to rise, the demand for effective diagnostic and therapeutic solutions, including radiopharmaceuticals, is expected to increase. The World Health Organization has reported a steady rise in cancer cases, which necessitates the use of advanced imaging techniques for early detection and treatment. This growing need for radiopharmaceuticals is likely to drive the demand for synthesizers that can produce high-quality isotopes efficiently, thereby supporting the overall market growth.

Advancements in Radiopharmaceutical Technologies

Technological innovations in radiopharmaceuticals are propelling the Radiopharmaceutical Synthesizer Market forward. The development of new radiotracers and improved synthesis methods enhances the efficacy and safety of radiopharmaceuticals. For instance, advancements in automated synthesizers allow for higher precision and reduced human error, which is crucial in the production of radiopharmaceuticals. The market is witnessing a shift towards more sophisticated synthesizers that can produce a wider range of isotopes, catering to diverse clinical needs. This trend is expected to drive market growth, as healthcare facilities seek to adopt cutting-edge technologies to improve patient outcomes.

Market Segment Insights

By Modality: PET (Largest) vs. SPECT (Fastest-Growing)

The Radiopharmaceutical Synthesizer Market is characterized by a diverse modality distribution. Within this arena, PET stands out as the largest segment, primarily due to its extensive application in oncology and its increasing adoption in various clinical settings. SPECT, while smaller in market share, shows significant potential for growth driven by advances in imaging technologies and the rising incidence of chronic diseases, positioning it as the fastest-growing segment in the market. In analyzing growth trends, PET's dominance can be attributed to its established presence in diagnostic imaging, providing high-resolution images that assist in accurate disease detection. SPECT is rapidly gaining traction due to innovations that improve imaging speed and resolution, alongside a growing focus on personalized medicine. The demand for early diagnosis and targeted therapies further accelerates the growth trajectory of both PET and SPECT modalities in the radiopharmaceutical synthesizer landscape.

Modality: PET (Dominant) vs. SPECT (Emerging)

PET, or Positron Emission Tomography, is the dominant modality in the Radiopharmaceutical Synthesizer Market, celebrated for its unmatched imaging capabilities and crucial role in cancer diagnostics. Its ability to provide metabolic information of tissues renders PET indispensable in clinical decision-making. By contrast, SPECT, or Single Photon Emission Computed Tomography, emerges as a promising segment with growing acceptance in nuclear medicine. Though it traditionally lagged behind PET, advancements in technology, coupled with a shift towards earlier detection of diseases, are facilitating its expansion. Both modalities illustrate significant value propositions, with PET leading in terms of established application, while SPECT captures attention as an emerging alternative, reflecting the dynamic shifts within the radiopharmaceutical landscape.

By Application: Oncology (Largest) vs. Cardiology (Fastest-Growing)

In the Radiopharmaceutical Synthesizer Market, Oncology currently holds the largest market share among various applications, driven by the rising prevalence of cancer cases globally. It dominates due to the increasing adoption of advanced imaging techniques and therapies that utilize radiopharmaceuticals, thus facilitating improved diagnostic accuracy and treatment options. Cardiology follows as a rapidly emerging segment, leveraging advancements in cardiac imaging and the growing focus on heart disease management.

Oncology (Dominant) vs. Cardiology (Emerging)

Oncology remains the dominant application in the Radiopharmaceutical Synthesizer Market, characterized by extensive use in tumor targeting and diagnosis, which significantly enhances patient outcomes. This segment benefits from robust R&D efforts aimed at developing innovative radiopharmaceuticals that provide precise imaging and personalized treatment. Conversely, Cardiology is an emerging powerhouse, witnessing remarkable growth due to the increasing risk factors for cardiovascular diseases and the advent of novel radiopharmaceutical agents for myocardial perfusion imaging. Its rise is fueled by healthcare initiatives aimed at early diagnosis and management of heart conditions, ensuring better patient care.

By Radioisotope: Fluorine-18 (Largest) vs. Gallium-68 (Fastest-Growing)

The Radiopharmaceutical Synthesizer Market is characterized by a diverse range of radioisotopes, with Fluorine-18 holding the largest share due to its extensive use in positron emission tomography (PET) imaging. Following closely is Gallium-68, which is rapidly gaining traction owing to its application in targeted radiotherapy and diagnostic imaging. Carbon-11 and other isotopes share a smaller pie, contributing to the overall market but lacking the prominence of Fluorine-18 and Gallium-68. This distribution underscores the competitive landscape within the market, influencing strategic developments among players.

Fluorine-18 (Dominant) vs. Gallium-68 (Emerging)

Fluorine-18 is a dominant component in the Radiopharmaceutical Synthesizer Market, primarily recognized for its pivotal role in facilitating advanced imaging techniques like PET scans, which are crucial for cancer diagnosis and treatment evaluation. This radioisotope is favored for its optimal half-life and radioactive properties, allowing for precise imaging. On the other hand, Gallium-68 is emerging as a vital player, owing to its unique applications in theranostics, a combination of therapy and diagnostics, enhancing personalized treatment strategies. As healthcare increasingly leans towards tailored therapies, the demand for Gallium-68 is projected to rise, positioning it as a key player in evolving treatment paradigms.

By Synthesis Method: Solid-Phase (Largest) vs. Liquid-Phase (Fastest-Growing)

In the Radiopharmaceutical Synthesizer Market, the Solid-Phase synthesis method holds the largest market share due to its established use in clinical applications and efficiency in producing high-quality radiopharmaceuticals. Liquid-Phase synthesis follows, with significant contributions from its versatility in creating a range of compounds with varying complexity. Gas-Phase synthesis, while important, occupies a smaller share, catering mostly to niche applications, while Others reflect supplementary methods with emerging relevance.

Synthesis Methods: Solid-Phase (Dominant) vs. Liquid-Phase (Emerging)

The Solid-Phase synthesis method is dominant in the Radiopharmaceutical Synthesizer Market, primarily due to its robustness and efficiency in producing stable yet reactive compounds that are essential for diagnostic and therapeutic applications. Its well-validated protocols make it the preferred choice in many clinical settings. On the other hand, Liquid-Phase synthesis is emerging rapidly, driven by advancements in technology that allow for greater flexibility and complexity in product design. This method is gaining traction as researchers seek novel compounds with enhanced treatment profiles, responding to the demand for more personalized medicine in the field of radiopharmaceuticals.

Get more detailed insights about Radiopharmaceutical Synthesizer Market
Request Free Sample

Regional Insights

North America : Market Leader in Innovation

North America is the largest market for radiopharmaceutical synthesizers, holding approximately 45% of the global market share. The region benefits from advanced healthcare infrastructure, significant investments in research and development, and a growing demand for diagnostic imaging. Regulatory support from agencies like the FDA further catalyzes market growth, ensuring safety and efficacy in radiopharmaceutical applications. The United States is the primary contributor, with key players such as GE Healthcare and Lantheus Medical Imaging leading the market. Canada also plays a significant role, focusing on innovative solutions and partnerships. The competitive landscape is characterized by continuous advancements in technology and a strong emphasis on regulatory compliance, ensuring high-quality products for healthcare providers.

Europe : Emerging Market with Growth Potential

Europe is the second-largest market for radiopharmaceutical synthesizers, accounting for approximately 30% of the global market share. The region is witnessing a surge in demand due to increasing investments in healthcare and advancements in nuclear medicine. Regulatory frameworks established by the European Medicines Agency (EMA) are pivotal in promoting innovation and ensuring patient safety, thus driving market growth. Leading countries include Germany, France, and the Netherlands, where companies like Siemens Healthineers and Bracco Imaging are prominent. The competitive landscape is evolving, with a focus on collaboration between public and private sectors to enhance research capabilities. The presence of established players and emerging startups fosters a dynamic environment for technological advancements in radiopharmaceuticals.

Asia-Pacific : Rapidly Growing Healthcare Sector

Asia-Pacific is rapidly emerging as a significant player in the radiopharmaceutical synthesizer market, holding about 20% of the global market share. The region's growth is driven by increasing healthcare expenditures, a rising prevalence of chronic diseases, and advancements in nuclear medicine technology. Government initiatives aimed at enhancing healthcare infrastructure and regulatory frameworks are also contributing to market expansion. Countries like Japan, China, and India are at the forefront, with a growing number of local manufacturers and collaborations with global players. The competitive landscape is characterized by a mix of established companies and new entrants, focusing on innovation and affordability. This dynamic environment is expected to attract further investments and enhance the availability of radiopharmaceuticals in the region.

Middle East and Africa : Untapped Market with Potential

The Middle East and Africa region is gradually emerging in the radiopharmaceutical synthesizer market, holding approximately 5% of the global market share. The growth is primarily driven by increasing healthcare investments, rising awareness of nuclear medicine, and the need for advanced diagnostic tools. Regulatory bodies are beginning to establish frameworks that support the safe use of radiopharmaceuticals, which is crucial for market development. Countries like South Africa and the UAE are leading the way, with initiatives aimed at enhancing healthcare services and attracting foreign investments. The competitive landscape is still developing, with opportunities for both local and international players to establish a presence. As the region continues to invest in healthcare infrastructure, the demand for radiopharmaceuticals is expected to rise significantly.

Radiopharmaceutical Synthesizer Market Regional Image

Key Players and Competitive Insights

Leading players in the industry of the Radiopharmaceutical Synthesizer Market regularly try to develop new products to stay competitive and match the rapid changes in the industry. Nowadays, many of the leading players in the industry and key manufacturers target their investments in the research and development of products. In many market areas, particularly in the given, the development landscape is heavily shaped by various forms of strategic partnerships and collaborations between the major players. The latter is expected to take advantage of the arrangements to exploit shared synergies and facilitate the exchange of practices and solutions between different market players. The competitive landscape is likely to remain active in the upcoming years, partly due to the emergence of new entrants and the deployment of new technologies in the industry. GE Healthcare is the manufacturer of different radiopharmaceutical synthesizers and reagents. The company strives on an ongoing basis to create new, innovative ideas that may be transformed into new product lines. In many respects, GE Healthcare optimized its operations with the help of such technologies as the FASTlab synthesizer. This device provides its users with valuable opportunities for rapid, efficient, and flexible radiopharmaceutical synthesis. Being a truly global company, GE Healthcare gains many benefits from its large market presence and distribution network. The company also strives to provide high-quality customer support and post-market training and assistance to those users who are newly introduced to their products. IBA is a prominent manufacturer of radioisotopes and radiopharmaceuticals. As always, the company produces high-quality products in compliance with relevant regulatory requirements on radiochemistry and radiation protection. IBA also developed important partnerships with leading players in the pharmaceutical and biotechnology industry, which provides the company with access to new markets and distribution networks. Many of the company's products are outstanding and innovative, and its operations are further advanced by the introduction of the company's products in new territories.

Key Companies in the Radiopharmaceutical Synthesizer Market include

Industry Developments

The global radiopharmaceutical synthesizer market is poised to grow significantly in the coming years, driven by increasing demand for personalized medicine and advancements in nuclear medicine. Key factors contributing to this growth include the rising prevalence of chronic diseases, increasing adoption of theranostic procedures, and technological advancements in radiopharmaceutical synthesis.

Recent news developments in the market include the strategic partnership between IBA and Curium to enhance radioisotope production capabilities and the acquisition of GE Healthcare's radiopharmaceutical business by Cardinal Health, strengthening its position in the nuclear medicine supply chain. These developments highlight the growing emphasis on innovation and consolidation within the industry.

Future Outlook

Radiopharmaceutical Synthesizer Market Future Outlook

The Radiopharmaceutical Synthesizer Market is projected to grow at a 4.42% CAGR from 2025 to 2035, driven by technological advancements, increasing demand for diagnostic imaging, and expanding applications in therapeutics.

New opportunities lie in:

  • Development of compact, portable synthesizers for point-of-care applications.
  • Integration of AI for enhanced synthesis efficiency and quality control.
  • Expansion into emerging markets with tailored product offerings.

By 2035, the market is expected to achieve robust growth, positioning itself as a leader in medical imaging solutions.

Market Segmentation

Radiopharmaceutical Synthesizer Market Modality Outlook

  • PET
  • SPECT
  • Others

Radiopharmaceutical Synthesizer Market Application Outlook

  • Oncology
  • Cardiology
  • Neurology
  • Others

Radiopharmaceutical Synthesizer Market Radioisotope Outlook

  • Fluorine-18
  • Carbon-11
  • Gallium-68
  • Others

Radiopharmaceutical Synthesizer Market Synthesis Method Outlook

  • Solid-Phase
  • Liquid-Phase
  • Gas-Phase
  • Others

Report Scope

MARKET SIZE 2024 3.108(USD Billion)
MARKET SIZE 2025 3.246(USD Billion)
MARKET SIZE 2035 5.002(USD Billion)
COMPOUND ANNUAL GROWTH RATE (CAGR) 4.42% (2025 - 2035)
REPORT COVERAGE Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR 2024
Market Forecast Period 2025 - 2035
Historical Data 2019 - 2024
Market Forecast Units USD Billion
Key Companies Profiled GE Healthcare (US), Siemens Healthineers (DE), Philips Healthcare (NL), Elekta (SE), Bracco Imaging (IT), Lantheus Medical Imaging (US), NorthStar Medical Radioisotopes (US), Radiopharma (FR), IThemba LABS (ZA)
Segments Covered Modality, Application, Radioisotope, Synthesis Method, Regional
Key Market Opportunities Advancements in automation and precision drive growth in the Radiopharmaceutical Synthesizer Market.
Key Market Dynamics Technological advancements and regulatory changes drive innovation and competition in the radiopharmaceutical synthesizer market.
Countries Covered North America, Europe, APAC, South America, MEA
Author
Author
Author Profile
Rahul Gotadki LinkedIn
Research Manager
He holds an experience of about 9+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc.
Get In Touch
Leave a Comment

FAQs

What is the projected market valuation of the Radiopharmaceutical Synthesizer Market by 2035?

<p>The Radiopharmaceutical Synthesizer Market is projected to reach a valuation of 5.002 USD Billion by 2035.</p>

What was the market valuation of the Radiopharmaceutical Synthesizer Market in 2024?

<p>In 2024, the market valuation of the Radiopharmaceutical Synthesizer Market was 3.108 USD Billion.</p>

What is the expected CAGR for the Radiopharmaceutical Synthesizer Market during the forecast period 2025 - 2035?

<p>The expected CAGR for the Radiopharmaceutical Synthesizer Market during the forecast period 2025 - 2035 is 4.42%.</p>

Which companies are considered key players in the Radiopharmaceutical Synthesizer Market?

<p>Key players in the Radiopharmaceutical Synthesizer Market include GE Healthcare, Siemens Healthineers, Philips Healthcare, and others.</p>

What are the main modalities contributing to the Radiopharmaceutical Synthesizer Market?

<p>The main modalities include PET, SPECT, and others, with PET projected to grow from 1.5 to 2.4 USD Billion.</p>

How does the oncology application segment perform in the Radiopharmaceutical Synthesizer Market?

<p>The oncology application segment is expected to grow from 1.5 to 2.4 USD Billion, indicating strong demand.</p>

What is the market performance of the liquid-phase synthesis method in 2025?

<p>The liquid-phase synthesis method is projected to grow from 1.2 to 1.8 USD Billion, reflecting its importance in the market.</p>

Which radioisotope is expected to show significant growth in the Radiopharmaceutical Synthesizer Market?

<p>Fluorine-18 is expected to show growth from 0.8 to 0.9 USD Billion, highlighting its relevance in radiopharmaceuticals.</p>

What is the expected growth for the gas-phase synthesis method by 2035?

<p>The gas-phase synthesis method is projected to grow from 0.6 to 0.9 USD Billion by 2035.</p>

How does the Radiopharmaceutical Synthesizer Market's growth compare across different applications?

<p>The market shows varied growth across applications, with cardiology expected to rise from 0.9 to 1.4 USD Billion.</p>

Research Approach

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY 
1.1. Market Overview 
1.2. Key Findings 
1.3. Market Segmentation 
1.4. Competitive Landscape 
1.5. Challenges and Opportunities 
1.6. Future Outlook 
2. MARKET INTRODUCTION 
2.1. Definition 
2.2. Scope of the study 
2.2.1. Research Objective 
2.2.2. Assumption 
2.2.3. Limitations 
3. RESEARCH METHODOLOGY 
3.1. Overview 
3.2. Data Mining 
3.3. Secondary Research 
3.4. Primary Research 
3.4.1. Primary Interviews and Information Gathering Process 
3.4.2. Breakdown of Primary Respondents 
3.5. Forecasting Model 
3.6. Market Size Estimation 
3.6.1. Bottom-Up Approach 
3.6.2. Top-Down Approach 
3.7. Data Triangulation 
3.8. Validation 
4. MARKET DYNAMICS 
4.1. Overview 
4.2. Drivers 
4.3. Restraints 
4.4. Opportunities 
5. MARKET FACTOR ANALYSIS 
5.1. Value chain Analysis 
5.2. Porter's Five Forces Analysis 
5.2.1. Bargaining Power of Suppliers 
5.2.2. Bargaining Power of Buyers 
5.2.3. Threat of New Entrants 
5.2.4. Threat of Substitutes 
5.2.5. Intensity of Rivalry 
5.3. COVID-19 Impact Analysis 
5.3.1. Market Impact Analysis 
5.3.2. Regional Impact 
5.3.3. Opportunity and Threat Analysis 
6. RADIOPHARMACEUTICAL SYNTHESIZER MARKET, BY MODALITY (USD BILLION) 
6.1. PET 
6.2. SPECT 
6.3. Others 
7. RADIOPHARMACEUTICAL SYNTHESIZER MARKET, BY APPLICATION (USD BILLION) 
7.1. Oncology 
7.2. Cardiology 
7.3. Neurology 
7.4. Others 
8. RADIOPHARMACEUTICAL SYNTHESIZER MARKET, BY RADIOISOTOPE (USD BILLION) 
8.1. Fluorine-18 
8.2. Carbon-11 
8.3. Gallium-68 
8.4. Others 
9. RADIOPHARMACEUTICAL SYNTHESIZER MARKET, BY SYNTHESIS METHOD (USD BILLION) 
9.1. Solid-Phase 
9.2. Liquid-Phase 
9.3. Gas-Phase 
9.4. Others 
10. RADIOPHARMACEUTICAL SYNTHESIZER MARKET, BY REGIONAL (USD BILLION) 
10.1. North America 
10.1.1. US 
10.1.2. Canada 
10.2. Europe 
10.2.1. Germany 
10.2.2. UK 
10.2.3. France 
10.2.4. Russia 
10.2.5. Italy 
10.2.6. Spain 
10.2.7. Rest of Europe 
10.3. APAC 
10.3.1. China 
10.3.2. India 
10.3.3. Japan 
10.3.4. South Korea 
10.3.5. Malaysia 
10.3.6. Thailand 
10.3.7. Indonesia 
10.3.8. Rest of APAC 
10.4. South America 
10.4.1. Brazil 
10.4.2. Mexico 
10.4.3. Argentina 
10.4.4. Rest of South America 
10.5. MEA 
10.5.1. GCC Countries 
10.5.2. South Africa 
10.5.3. Rest of MEA 
11. COMPETITIVE LANDSCAPE 
11.1. Overview 
11.2. Competitive Analysis 
11.3. Market share Analysis 
11.4. Major Growth Strategy in the Radiopharmaceutical Synthesizer Market 
11.5. Competitive Benchmarking 
11.6. Leading Players in Terms of Number of Developments in the Radiopharmaceutical Synthesizer Market 
11.7. Key developments and growth strategies 
11.7.1. New Product Launch/Service Deployment 
11.7.2. Merger & Acquisitions 
11.7.3. Joint Ventures 
11.8. Major Players Financial Matrix 
11.8.1. Sales and Operating Income 
11.8.2. Major Players R&D Expenditure. 2023 
12. COMPANY PROFILES 
12.1. Nuclear Fields 
12.1.1. Financial Overview 
12.1.2. Products Offered 
12.1.3. Key Developments 
12.1.4. SWOT Analysis 
12.1.5. Key Strategies 
12.2. GE Healthcare 
12.2.1. Financial Overview 
12.2.2. Products Offered 
12.2.3. Key Developments 
12.2.4. SWOT Analysis 
12.2.5. Key Strategies 
12.3. Positron Corporation 
12.3.1. Financial Overview 
12.3.2. Products Offered 
12.3.3. Key Developments 
12.3.4. SWOT Analysis 
12.3.5. Key Strategies 
12.4. IBA Molecular 
12.4.1. Financial Overview 
12.4.2. Products Offered 
12.4.3. Key Developments 
12.4.4. SWOT Analysis 
12.4.5. Key Strategies 
12.5. Lantheus Medical Imaging 
12.5.1. Financial Overview 
12.5.2. Products Offered 
12.5.3. Key Developments 
12.5.4. SWOT Analysis 
12.5.5. Key Strategies 
12.6. TransnetYX 
12.6.1. Financial Overview 
12.6.2. Products Offered 
12.6.3. Key Developments 
12.6.4. SWOT Analysis 
12.6.5. Key Strategies 
12.7. Curium Pharma 
12.7.1. Financial Overview 
12.7.2. Products Offered 
12.7.3. Key Developments 
12.7.4. SWOT Analysis 
12.7.5. Key Strategies 
12.8. Eckert Ziegler 
12.8.1. Financial Overview 
12.8.2. Products Offered 
12.8.3. Key Developments 
12.8.4. SWOT Analysis 
12.8.5. Key Strategies 
12.9. Siemens Healthineers 
12.9.1. Financial Overview 
12.9.2. Products Offered 
12.9.3. Key Developments 
12.9.4. SWOT Analysis 
12.9.5. Key Strategies 
12.10. Samyung Radiopharmaceuticals 
12.10.1. Financial Overview 
12.10.2. Products Offered 
12.10.3. Key Developments 
12.10.4. SWOT Analysis 
12.10.5. Key Strategies 
12.11. RadPharm Theranostics 
12.11.1. Financial Overview 
12.11.2. Products Offered 
12.11.3. Key Developments 
12.11.4. SWOT Analysis 
12.11.5. Key Strategies 
12.12. Beijing Atom Hightech 
12.12.1. Financial Overview 
12.12.2. Products Offered 
12.12.3. Key Developments 
12.12.4. SWOT Analysis 
12.12.5. Key Strategies 
12.13. Wuhan Union Hospital 
12.13.1. Financial Overview 
12.13.2. Products Offered 
12.13.3. Key Developments 
12.13.4. SWOT Analysis 
12.13.5. Key Strategies 
12.14. CRC Cyclotron 
12.14.1. Financial Overview 
12.14.2. Products Offered 
12.14.3. Key Developments 
12.14.4. SWOT Analysis 
12.14.5. Key Strategies 
12.15. Bracco Imaging 
12.15.1. Financial Overview 
12.15.2. Products Offered 
12.15.3. Key Developments 
12.15.4. SWOT Analysis 
12.15.5. Key Strategies 
13. APPENDIX 
13.1. References 
13.2. Related Reports 
LIST OF TABLES
TABLE 1. LIST OF ASSUMPTIONS 
TABLE 2. NORTH AMERICA RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY MODALITY, 2019-2032 (USD BILLIONS) 
TABLE 3. NORTH AMERICA RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2032 (USD BILLIONS) 
TABLE 4. NORTH AMERICA RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY RADIOISOTOPE, 2019-2032 (USD BILLIONS) 
TABLE 5. NORTH AMERICA RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY SYNTHESIS METHOD, 2019-2032 (USD BILLIONS) 
TABLE 6. NORTH AMERICA RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS) 
TABLE 7. US RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY MODALITY, 2019-2032 (USD BILLIONS) 
TABLE 8. US RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2032 (USD BILLIONS) 
TABLE 9. US RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY RADIOISOTOPE, 2019-2032 (USD BILLIONS) 
TABLE 10. US RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY SYNTHESIS METHOD, 2019-2032 (USD BILLIONS) 
TABLE 11. US RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS) 
TABLE 12. CANADA RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY MODALITY, 2019-2032 (USD BILLIONS) 
TABLE 13. CANADA RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2032 (USD BILLIONS) 
TABLE 14. CANADA RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY RADIOISOTOPE, 2019-2032 (USD BILLIONS) 
TABLE 15. CANADA RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY SYNTHESIS METHOD, 2019-2032 (USD BILLIONS) 
TABLE 16. CANADA RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS) 
TABLE 17. EUROPE RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY MODALITY, 2019-2032 (USD BILLIONS) 
TABLE 18. EUROPE RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2032 (USD BILLIONS) 
TABLE 19. EUROPE RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY RADIOISOTOPE, 2019-2032 (USD BILLIONS) 
TABLE 20. EUROPE RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY SYNTHESIS METHOD, 2019-2032 (USD BILLIONS) 
TABLE 21. EUROPE RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS) 
TABLE 22. GERMANY RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY MODALITY, 2019-2032 (USD BILLIONS) 
TABLE 23. GERMANY RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2032 (USD BILLIONS) 
TABLE 24. GERMANY RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY RADIOISOTOPE, 2019-2032 (USD BILLIONS) 
TABLE 25. GERMANY RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY SYNTHESIS METHOD, 2019-2032 (USD BILLIONS) 
TABLE 26. GERMANY RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS) 
TABLE 27. UK RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY MODALITY, 2019-2032 (USD BILLIONS) 
TABLE 28. UK RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2032 (USD BILLIONS) 
TABLE 29. UK RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY RADIOISOTOPE, 2019-2032 (USD BILLIONS) 
TABLE 30. UK RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY SYNTHESIS METHOD, 2019-2032 (USD BILLIONS) 
TABLE 31. UK RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS) 
TABLE 32. FRANCE RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY MODALITY, 2019-2032 (USD BILLIONS) 
TABLE 33. FRANCE RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2032 (USD BILLIONS) 
TABLE 34. FRANCE RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY RADIOISOTOPE, 2019-2032 (USD BILLIONS) 
TABLE 35. FRANCE RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY SYNTHESIS METHOD, 2019-2032 (USD BILLIONS) 
TABLE 36. FRANCE RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS) 
TABLE 37. RUSSIA RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY MODALITY, 2019-2032 (USD BILLIONS) 
TABLE 38. RUSSIA RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2032 (USD BILLIONS) 
TABLE 39. RUSSIA RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY RADIOISOTOPE, 2019-2032 (USD BILLIONS) 
TABLE 40. RUSSIA RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY SYNTHESIS METHOD, 2019-2032 (USD BILLIONS) 
TABLE 41. RUSSIA RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS) 
TABLE 42. ITALY RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY MODALITY, 2019-2032 (USD BILLIONS) 
TABLE 43. ITALY RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2032 (USD BILLIONS) 
TABLE 44. ITALY RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY RADIOISOTOPE, 2019-2032 (USD BILLIONS) 
TABLE 45. ITALY RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY SYNTHESIS METHOD, 2019-2032 (USD BILLIONS) 
TABLE 46. ITALY RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS) 
TABLE 47. SPAIN RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY MODALITY, 2019-2032 (USD BILLIONS) 
TABLE 48. SPAIN RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2032 (USD BILLIONS) 
TABLE 49. SPAIN RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY RADIOISOTOPE, 2019-2032 (USD BILLIONS) 
TABLE 50. SPAIN RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY SYNTHESIS METHOD, 2019-2032 (USD BILLIONS) 
TABLE 51. SPAIN RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS) 
TABLE 52. REST OF EUROPE RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY MODALITY, 2019-2032 (USD BILLIONS) 
TABLE 53. REST OF EUROPE RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2032 (USD BILLIONS) 
TABLE 54. REST OF EUROPE RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY RADIOISOTOPE, 2019-2032 (USD BILLIONS) 
TABLE 55. REST OF EUROPE RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY SYNTHESIS METHOD, 2019-2032 (USD BILLIONS) 
TABLE 56. REST OF EUROPE RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS) 
TABLE 57. APAC RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY MODALITY, 2019-2032 (USD BILLIONS) 
TABLE 58. APAC RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2032 (USD BILLIONS) 
TABLE 59. APAC RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY RADIOISOTOPE, 2019-2032 (USD BILLIONS) 
TABLE 60. APAC RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY SYNTHESIS METHOD, 2019-2032 (USD BILLIONS) 
TABLE 61. APAC RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS) 
TABLE 62. CHINA RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY MODALITY, 2019-2032 (USD BILLIONS) 
TABLE 63. CHINA RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2032 (USD BILLIONS) 
TABLE 64. CHINA RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY RADIOISOTOPE, 2019-2032 (USD BILLIONS) 
TABLE 65. CHINA RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY SYNTHESIS METHOD, 2019-2032 (USD BILLIONS) 
TABLE 66. CHINA RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS) 
TABLE 67. INDIA RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY MODALITY, 2019-2032 (USD BILLIONS) 
TABLE 68. INDIA RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2032 (USD BILLIONS) 
TABLE 69. INDIA RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY RADIOISOTOPE, 2019-2032 (USD BILLIONS) 
TABLE 70. INDIA RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY SYNTHESIS METHOD, 2019-2032 (USD BILLIONS) 
TABLE 71. INDIA RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS) 
TABLE 72. JAPAN RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY MODALITY, 2019-2032 (USD BILLIONS) 
TABLE 73. JAPAN RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2032 (USD BILLIONS) 
TABLE 74. JAPAN RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY RADIOISOTOPE, 2019-2032 (USD BILLIONS) 
TABLE 75. JAPAN RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY SYNTHESIS METHOD, 2019-2032 (USD BILLIONS) 
TABLE 76. JAPAN RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS) 
TABLE 77. SOUTH KOREA RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY MODALITY, 2019-2032 (USD BILLIONS) 
TABLE 78. SOUTH KOREA RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2032 (USD BILLIONS) 
TABLE 79. SOUTH KOREA RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY RADIOISOTOPE, 2019-2032 (USD BILLIONS) 
TABLE 80. SOUTH KOREA RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY SYNTHESIS METHOD, 2019-2032 (USD BILLIONS) 
TABLE 81. SOUTH KOREA RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS) 
TABLE 82. MALAYSIA RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY MODALITY, 2019-2032 (USD BILLIONS) 
TABLE 83. MALAYSIA RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2032 (USD BILLIONS) 
TABLE 84. MALAYSIA RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY RADIOISOTOPE, 2019-2032 (USD BILLIONS) 
TABLE 85. MALAYSIA RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY SYNTHESIS METHOD, 2019-2032 (USD BILLIONS) 
TABLE 86. MALAYSIA RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS) 
TABLE 87. THAILAND RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY MODALITY, 2019-2032 (USD BILLIONS) 
TABLE 88. THAILAND RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2032 (USD BILLIONS) 
TABLE 89. THAILAND RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY RADIOISOTOPE, 2019-2032 (USD BILLIONS) 
TABLE 90. THAILAND RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY SYNTHESIS METHOD, 2019-2032 (USD BILLIONS) 
TABLE 91. THAILAND RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS) 
TABLE 92. INDONESIA RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY MODALITY, 2019-2032 (USD BILLIONS) 
TABLE 93. INDONESIA RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2032 (USD BILLIONS) 
TABLE 94. INDONESIA RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY RADIOISOTOPE, 2019-2032 (USD BILLIONS) 
TABLE 95. INDONESIA RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY SYNTHESIS METHOD, 2019-2032 (USD BILLIONS) 
TABLE 96. INDONESIA RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS) 
TABLE 97. REST OF APAC RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY MODALITY, 2019-2032 (USD BILLIONS) 
TABLE 98. REST OF APAC RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2032 (USD BILLIONS) 
TABLE 99. REST OF APAC RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY RADIOISOTOPE, 2019-2032 (USD BILLIONS) 
TABLE 100. REST OF APAC RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY SYNTHESIS METHOD, 2019-2032 (USD BILLIONS) 
TABLE 101. REST OF APAC RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS) 
TABLE 102. SOUTH AMERICA RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY MODALITY, 2019-2032 (USD BILLIONS) 
TABLE 103. SOUTH AMERICA RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2032 (USD BILLIONS) 
TABLE 104. SOUTH AMERICA RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY RADIOISOTOPE, 2019-2032 (USD BILLIONS) 
TABLE 105. SOUTH AMERICA RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY SYNTHESIS METHOD, 2019-2032 (USD BILLIONS) 
TABLE 106. SOUTH AMERICA RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS) 
TABLE 107. BRAZIL RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY MODALITY, 2019-2032 (USD BILLIONS) 
TABLE 108. BRAZIL RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2032 (USD BILLIONS) 
TABLE 109. BRAZIL RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY RADIOISOTOPE, 2019-2032 (USD BILLIONS) 
TABLE 110. BRAZIL RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY SYNTHESIS METHOD, 2019-2032 (USD BILLIONS) 
TABLE 111. BRAZIL RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS) 
TABLE 112. MEXICO RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY MODALITY, 2019-2032 (USD BILLIONS) 
TABLE 113. MEXICO RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2032 (USD BILLIONS) 
TABLE 114. MEXICO RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY RADIOISOTOPE, 2019-2032 (USD BILLIONS) 
TABLE 115. MEXICO RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY SYNTHESIS METHOD, 2019-2032 (USD BILLIONS) 
TABLE 116. MEXICO RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS) 
TABLE 117. ARGENTINA RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY MODALITY, 2019-2032 (USD BILLIONS) 
TABLE 118. ARGENTINA RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2032 (USD BILLIONS) 
TABLE 119. ARGENTINA RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY RADIOISOTOPE, 2019-2032 (USD BILLIONS) 
TABLE 120. ARGENTINA RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY SYNTHESIS METHOD, 2019-2032 (USD BILLIONS) 
TABLE 121. ARGENTINA RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS) 
TABLE 122. REST OF SOUTH AMERICA RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY MODALITY, 2019-2032 (USD BILLIONS) 
TABLE 123. REST OF SOUTH AMERICA RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2032 (USD BILLIONS) 
TABLE 124. REST OF SOUTH AMERICA RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY RADIOISOTOPE, 2019-2032 (USD BILLIONS) 
TABLE 125. REST OF SOUTH AMERICA RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY SYNTHESIS METHOD, 2019-2032 (USD BILLIONS) 
TABLE 126. REST OF SOUTH AMERICA RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS) 
TABLE 127. MEA RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY MODALITY, 2019-2032 (USD BILLIONS) 
TABLE 128. MEA RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2032 (USD BILLIONS) 
TABLE 129. MEA RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY RADIOISOTOPE, 2019-2032 (USD BILLIONS) 
TABLE 130. MEA RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY SYNTHESIS METHOD, 2019-2032 (USD BILLIONS) 
TABLE 131. MEA RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS) 
TABLE 132. GCC COUNTRIES RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY MODALITY, 2019-2032 (USD BILLIONS) 
TABLE 133. GCC COUNTRIES RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2032 (USD BILLIONS) 
TABLE 134. GCC COUNTRIES RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY RADIOISOTOPE, 2019-2032 (USD BILLIONS) 
TABLE 135. GCC COUNTRIES RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY SYNTHESIS METHOD, 2019-2032 (USD BILLIONS) 
TABLE 136. GCC COUNTRIES RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS) 
TABLE 137. SOUTH AFRICA RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY MODALITY, 2019-2032 (USD BILLIONS) 
TABLE 138. SOUTH AFRICA RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2032 (USD BILLIONS) 
TABLE 139. SOUTH AFRICA RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY RADIOISOTOPE, 2019-2032 (USD BILLIONS) 
TABLE 140. SOUTH AFRICA RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY SYNTHESIS METHOD, 2019-2032 (USD BILLIONS) 
TABLE 141. SOUTH AFRICA RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS) 
TABLE 142. REST OF MEA RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY MODALITY, 2019-2032 (USD BILLIONS) 
TABLE 143. REST OF MEA RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2032 (USD BILLIONS) 
TABLE 144. REST OF MEA RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY RADIOISOTOPE, 2019-2032 (USD BILLIONS) 
TABLE 145. REST OF MEA RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY SYNTHESIS METHOD, 2019-2032 (USD BILLIONS) 
TABLE 146. REST OF MEA RADIOPHARMACEUTICAL SYNTHESIZER MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS) 
TABLE 147. PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL 
TABLE 148. ACQUISITION/PARTNERSHIP 

LIST OF FIGURES

FIGURE 1. MARKET SYNOPSIS 
FIGURE 2. NORTH AMERICA RADIOPHARMACEUTICAL SYNTHESIZER MARKET ANALYSIS 
FIGURE 3. US RADIOPHARMACEUTICAL SYNTHESIZER MARKET ANALYSIS BY MODALITY 
FIGURE 4. US RADIOPHARMACEUTICAL SYNTHESIZER MARKET ANALYSIS BY APPLICATION 
FIGURE 5. US RADIOPHARMACEUTICAL SYNTHESIZER MARKET ANALYSIS BY RADIOISOTOPE 
FIGURE 6. US RADIOPHARMACEUTICAL SYNTHESIZER MARKET ANALYSIS BY SYNTHESIS METHOD 
FIGURE 7. US RADIOPHARMACEUTICAL SYNTHESIZER MARKET ANALYSIS BY REGIONAL 
FIGURE 8. CANADA RADIOPHARMACEUTICAL SYNTHESIZER MARKET ANALYSIS BY MODALITY 
FIGURE 9. CANADA RADIOPHARMACEUTICAL SYNTHESIZER MARKET ANALYSIS BY APPLICATION 
FIGURE 10. CANADA RADIOPHARMACEUTICAL SYNTHESIZER MARKET ANALYSIS BY RADIOISOTOPE 
FIGURE 11. CANADA RADIOPHARMACEUTICAL SYNTHESIZER MARKET ANALYSIS BY SYNTHESIS METHOD 
FIGURE 12. CANADA RADIOPHARMACEUTICAL SYNTHESIZER MARKET ANALYSIS BY REGIONAL 
FIGURE 13. EUROPE RADIOPHARMACEUTICAL SYNTHESIZER MARKET ANALYSIS 
FIGURE 14. GERMANY RADIOPHARMACEUTICAL SYNTHESIZER MARKET ANALYSIS BY MODALITY 
FIGURE 15. GERMANY RADIOPHARMACEUTICAL SYNTHESIZER MARKET ANALYSIS BY APPLICATION 
FIGURE 16. GERMANY RADIOPHARMACEUTICAL SYNTHESIZER MARKET ANALYSIS BY RADIOISOTOPE 
FIGURE 17. GERMANY RADIOPHARMACEUTICAL SYNTHESIZER MARKET ANALYSIS BY SYNTHESIS METHOD 
FIGURE 18. GERMANY RADIOPHARMACEUTICAL SYNTHESIZER MARKET ANALYSIS BY REGIONAL 
FIGURE 19. UK RADIOPHARMACEUTICAL SYNTHESIZER MARKET ANALYSIS BY MODALITY 
FIGURE 20. UK RADIOPHARMACEUTICAL SYNTHESIZER MARKET ANALYSIS BY APPLICATION 
FIGURE 21. UK RADIOPHARMACEUTICAL SYNTHESIZER MARKET ANALYSIS BY RADIOISOTOPE 
FIGURE 22. UK RADIOPHARMACEUTICAL SYNTHESIZER MARKET ANALYSIS BY SYNTHESIS METHOD 
FIGURE 23. UK RADIOPHARMACEUTICAL SYNTHESIZER MARKET ANALYSIS BY REGIONAL 
FIGURE 24. FRANCE RADIOPHARMACEUTICAL SYNTHESIZER MARKET ANALYSIS BY MODALITY 
FIGURE 25. FRANCE RADIOPHARMACEUTICAL SYNTHESIZER MARKET ANALYSIS BY APPLICATION 
FIGURE 26. FRANCE RADIOPHARMACEUTICAL SYNTHESIZER MARKET ANALYSIS BY RADIOISOTOPE 
FIGURE 27. FRANCE RADIOPHARMACEUTICAL SYNTHESIZER MARKET ANALYSIS BY SYNTHESIS METHOD 
FIGURE 28. FRANCE RADIOPHARMACEUTICAL SYNTHESIZER MARKET ANALYSIS BY REGIONAL 
FIGURE 29. RUSSIA RADIOPHARMACEUTICAL SYNTHESIZER MARKET ANALYSIS BY MODALITY 
FIGURE 30. RUSSIA RADIOPHARMACEUTICAL SYNTHESIZER MARKET ANALYSIS BY APPLICATION 
FIGURE 31. RUSSIA RADIOPHARMACEUTICAL SYNTHESIZER MARKET ANALYSIS BY RADIOISOTOPE 
FIGURE 32. RUSSIA RADIOPHARMACEUTICAL SYNTHESIZER MARKET ANALYSIS BY SYNTHESIS METHOD 
FIGURE 33. RUSSIA RADIOPHARMACEUTICAL SYNTHESIZER MARKET ANALYSIS BY REGIONAL 
FIGURE 34. ITALY RADIOPHARMACEUTICAL SYNTHESIZER MARKET ANALYSIS BY MODALITY 
FIGURE 35. ITALY RADIOPHARMACEUTICAL SYNTHESIZER MARKET ANALYSIS BY APPLICATION 
FIGURE 36. ITALY RADIOPHARMACEUTICAL SYNTHESIZER MARKET ANALYSIS BY RADIOISOTOPE 
FIGURE 37. ITALY RADIOPHARMACEUTICAL SYNTHESIZER MARKET ANALYSIS BY SYNTHESIS METHOD 
FIGURE 38. ITALY RADIOPHARMACEUTICAL SYNTHESIZER MARKET ANALYSIS BY REGIONAL 
FIGURE 39. SPAIN RADIOPHARMACEUTICAL SYNTHESIZER MARKET ANALYSIS BY MODALITY 
FIGURE 40. SPAIN RADIOPHARMACEUTICAL SYNTHESIZER MARKET ANALYSIS BY APPLICATION 
FIGURE 41. SPAIN RADIOPHARMACEUTICAL SYNTHESIZER MARKET ANALYSIS BY RADIOISOTOPE 
FIGURE 42. SPAIN RADIOPHARMACEUTICAL SYNTHESIZER MARKET ANALYSIS BY SYNTHESIS METHOD 
FIGURE 43. SPAIN RADIOPHARMACEUTICAL SYNTHESIZER MARKET ANALYSIS BY REGIONAL 
FIGURE 44. REST OF EUROPE RADIOPHARMACEUTICAL SYNTHESIZER MARKET ANALYSIS BY MODALITY 
FIGURE 45. REST OF EUROPE RADIOPHARMACEUTICAL SYNTHESIZER MARKET ANALYSIS BY APPLICATION 
FIGURE 46. REST OF EUROPE RADIOPHARMACEUTICAL SYNTHESIZER MARKET ANALYSIS BY RADIOISOTOPE 
FIGURE 47. REST OF EUROPE RADIOPHARMACEUTICAL SYNTHESIZER MARKET ANALYSIS BY SYNTHESIS METHOD 
FIGURE 48. REST OF EUROPE RADIOPHARMACEUTICAL SYNTHESIZER MARKET ANALYSIS BY REGIONAL 
FIGURE 49. APAC RADIOPHARMACEUTICAL SYNTHESIZER MARKET ANALYSIS 
FIGURE 50. CHINA RADIOPHARMACEUTICAL SYNTHESIZER MARKET ANALYSIS BY MODALITY 
FIGURE 51. CHINA RADIOPHARMACEUTICAL SYNTHESIZER MARKET ANALYSIS BY APPLICATION 
FIGURE 52. CHINA RADIOPHARMACEUTICAL SYNTHESIZER MARKET ANALYSIS BY RADIOISOTOPE 
FIGURE 53. CHINA RADIOPHARMACEUTICAL SYNTHESIZER MARKET ANALYSIS BY SYNTHESIS METHOD 
FIGURE 54. CHINA RADIOPHARMACEUTICAL SYNTHESIZER MARKET ANALYSIS BY REGIONAL 
FIGURE 55. INDIA RADIOPHARMACEUTICAL SYNTHESIZER MARKET ANALYSIS BY MODALITY 
FIGURE 56. INDIA RADIOPHARMACEUTICAL SYNTHESIZER MARKET ANALYSIS BY APPLICATION 
FIGURE 57. INDIA RADIOPHARMACEUTICAL SYNTHESIZER MARKET ANALYSIS BY RADIOISOTOPE 
FIGURE 58. INDIA RADIOPHARMACEUTICAL SYNTHESIZER MARKET ANALYSIS BY SYNTHESIS METHOD 
FIGURE 59. INDIA RADIOPHARMACEUTICAL SYNTHESIZER MARKET ANALYSIS BY REGIONAL 
FIGURE 60. JAPAN RADIOPHARMACEUTICAL SYNTHESIZER MARKET ANALYSIS BY MODALITY 
FIGURE 61. JAPAN RADIOPHARMACEUTICAL SYNTHESIZER MARKET ANALYSIS BY APPLICATION 
FIGURE 62. JAPAN RADIOPHARMACEUTICAL SYNTHESIZER MARKET ANALYSIS BY RADIOISOTOPE 
FIGURE 63. JAPAN RADIOPHARMACEUTICAL SYNTHESIZER MARKET ANALYSIS BY SYNTHESIS METHOD 
FIGURE 64. JAPAN RADIOPHARMACEUTICAL SYNTHESIZER MARKET ANALYSIS BY REGIONAL 
FIGURE 65. SOUTH KOREA RADIOPHARMACEUTICAL SYNTHESIZER MARKET ANALYSIS BY MODALITY 
FIGURE 66. SOUTH KOREA RADIOPHARMACEUTICAL SYNTHESIZER MARKET ANALYSIS BY APPLICATION 
FIGURE 67. SOUTH KOREA RADIOPHARMACEUTICAL SYNTHESIZER MARKET ANALYSIS BY RADIOISOTOPE 
FIGURE 68. SOUTH KOREA RADIOPHARMACEUTICAL SYNTHESIZER MARKET ANALYSIS BY SYNTHESIS METHOD 
FIGURE 69. SOUTH KOREA RADIOPHARMACEUTICAL SYNTHESIZER MARKET ANALYSIS BY REGIONAL 
FIGURE 70. MALAYSIA RADIOPHARMACEUTICAL SYNTHESIZER MARKET ANALYSIS BY MODALITY 
FIGURE 71. MALAYSIA RADIOPHARMACEUTICAL SYNTHESIZER MARKET ANALYSIS BY APPLICATION 
FIGURE 72. MALAYSIA RADIOPHARMACEUTICAL SYNTHESIZER MARKET ANALYSIS BY RADIOISOTOPE 
FIGURE 73. MALAYSIA RADIOPHARMACEUTICAL SYNTHESIZER MARKET ANALYSIS BY SYNTHESIS METHOD 
FIGURE 74. MALAYSIA RADIOPHARMACEUTICAL SYNTHESIZER MARKET ANALYSIS BY REGIONAL 
FIGURE 75. THAILAND RADIOPHARMACEUTICAL SYNTHESIZER MARKET ANALYSIS BY MODALITY 
FIGURE 76. THAILAND RADIOPHARMACEUTICAL SYNTHESIZER MARKET ANALYSIS BY APPLICATION 
FIGURE 77. THAILAND RADIOPHARMACEUTICAL SYNTHESIZER MARKET ANALYSIS BY RADIOISOTOPE 
FIGURE 78. THAILAND RADIOPHARMACEUTICAL SYNTHESIZER MARKET ANALYSIS BY SYNTHESIS METHOD 
FIGURE 79. THAILAND RADIOPHARMACEUTICAL SYNTHESIZER MARKET ANALYSIS BY REGIONAL 
FIGURE 80. INDONESIA RADIOPHARMACEUTICAL SYNTHESIZER MARKET ANALYSIS BY MODALITY 
FIGURE 81. INDONESIA RADIOPHARMACEUTICAL SYNTHESIZER MARKET ANALYSIS BY APPLICATION 
FIGURE 82. INDONESIA RADIOPHARMACEUTICAL SYNTHESIZER MARKET ANALYSIS BY RADIOISOTOPE 
FIGURE 83. INDONESIA RADIOPHARMACEUTICAL SYNTHESIZER MARKET ANALYSIS BY SYNTHESIS METHOD 
FIGURE 84. INDONESIA RADIOPHARMACEUTICAL SYNTHESIZER MARKET ANALYSIS BY REGIONAL 
FIGURE 85. REST OF APAC RADIOPHARMACEUTICAL SYNTHESIZER MARKET ANALYSIS BY MODALITY 
FIGURE 86. REST OF APAC RADIOPHARMACEUTICAL SYNTHESIZER MARKET ANALYSIS BY APPLICATION 
FIGURE 87. REST OF APAC RADIOPHARMACEUTICAL SYNTHESIZER MARKET ANALYSIS BY RADIOISOTOPE 
FIGURE 88. REST OF APAC RADIOPHARMACEUTICAL SYNTHESIZER MARKET ANALYSIS BY SYNTHESIS METHOD 
FIGURE 89. REST OF APAC RADIOPHARMACEUTICAL SYNTHESIZER MARKET ANALYSIS BY REGIONAL 
FIGURE 90. SOUTH AMERICA RADIOPHARMACEUTICAL SYNTHESIZER MARKET ANALYSIS 
FIGURE 91. BRAZIL RADIOPHARMACEUTICAL SYNTHESIZER MARKET ANALYSIS BY MODALITY 
FIGURE 92. BRAZIL RADIOPHARMACEUTICAL SYNTHESIZER MARKET ANALYSIS BY APPLICATION 
FIGURE 93. BRAZIL RADIOPHARMACEUTICAL SYNTHESIZER MARKET ANALYSIS BY RADIOISOTOPE 
FIGURE 94. BRAZIL RADIOPHARMACEUTICAL SYNTHESIZER MARKET ANALYSIS BY SYNTHESIS METHOD 
FIGURE 95. BRAZIL RADIOPHARMACEUTICAL SYNTHESIZER MARKET ANALYSIS BY REGIONAL 
FIGURE 96. MEXICO RADIOPHARMACEUTICAL SYNTHESIZER MARKET ANALYSIS BY MODALITY 
FIGURE 97. MEXICO RADIOPHARMACEUTICAL SYNTHESIZER MARKET ANALYSIS BY APPLICATION 
FIGURE 98. MEXICO RADIOPHARMACEUTICAL SYNTHESIZER MARKET ANALYSIS BY RADIOISOTOPE 
FIGURE 99. MEXICO RADIOPHARMACEUTICAL SYNTHESIZER MARKET ANALYSIS BY SYNTHESIS METHOD 
FIGURE 100. MEXICO RADIOPHARMACEUTICAL SYNTHESIZER MARKET ANALYSIS BY REGIONAL 
FIGURE 101. ARGENTINA RADIOPHARMACEUTICAL SYNTHESIZER MARKET ANALYSIS BY MODALITY 
FIGURE 102. ARGENTINA RADIOPHARMACEUTICAL SYNTHESIZER MARKET ANALYSIS BY APPLICATION 
FIGURE 103. ARGENTINA RADIOPHARMACEUTICAL SYNTHESIZER MARKET ANALYSIS BY RADIOISOTOPE 
FIGURE 104. ARGENTINA RADIOPHARMACEUTICAL SYNTHESIZER MARKET ANALYSIS BY SYNTHESIS METHOD 
FIGURE 105. ARGENTINA RADIOPHARMACEUTICAL SYNTHESIZER MARKET ANALYSIS BY REGIONAL 
FIGURE 106. REST OF SOUTH AMERICA RADIOPHARMACEUTICAL SYNTHESIZER MARKET ANALYSIS BY MODALITY 
FIGURE 107. REST OF SOUTH AMERICA RADIOPHARMACEUTICAL SYNTHESIZER MARKET ANALYSIS BY APPLICATION 
FIGURE 108. REST OF SOUTH AMERICA RADIOPHARMACEUTICAL SYNTHESIZER MARKET ANALYSIS BY RADIOISOTOPE 
FIGURE 109. REST OF SOUTH AMERICA RADIOPHARMACEUTICAL SYNTHESIZER MARKET ANALYSIS BY SYNTHESIS METHOD 
FIGURE 110. REST OF SOUTH AMERICA RADIOPHARMACEUTICAL SYNTHESIZER MARKET ANALYSIS BY REGIONAL 
FIGURE 111. MEA RADIOPHARMACEUTICAL SYNTHESIZER MARKET ANALYSIS 
FIGURE 112. GCC COUNTRIES RADIOPHARMACEUTICAL SYNTHESIZER MARKET ANALYSIS BY MODALITY 
FIGURE 113. GCC COUNTRIES RADIOPHARMACEUTICAL SYNTHESIZER MARKET ANALYSIS BY APPLICATION 
FIGURE 114. GCC COUNTRIES RADIOPHARMACEUTICAL SYNTHESIZER MARKET ANALYSIS BY RADIOISOTOPE 
FIGURE 115. GCC COUNTRIES RADIOPHARMACEUTICAL SYNTHESIZER MARKET ANALYSIS BY SYNTHESIS METHOD 
FIGURE 116. GCC COUNTRIES RADIOPHARMACEUTICAL SYNTHESIZER MARKET ANALYSIS BY REGIONAL 
FIGURE 117. SOUTH AFRICA RADIOPHARMACEUTICAL SYNTHESIZER MARKET ANALYSIS BY MODALITY 
FIGURE 118. SOUTH AFRICA RADIOPHARMACEUTICAL SYNTHESIZER MARKET ANALYSIS BY APPLICATION 
FIGURE 119. SOUTH AFRICA RADIOPHARMACEUTICAL SYNTHESIZER MARKET ANALYSIS BY RADIOISOTOPE 
FIGURE 120. SOUTH AFRICA RADIOPHARMACEUTICAL SYNTHESIZER MARKET ANALYSIS BY SYNTHESIS METHOD 
FIGURE 121. SOUTH AFRICA RADIOPHARMACEUTICAL SYNTHESIZER MARKET ANALYSIS BY REGIONAL 
FIGURE 122. REST OF MEA RADIOPHARMACEUTICAL SYNTHESIZER MARKET ANALYSIS BY MODALITY 
FIGURE 123. REST OF MEA RADIOPHARMACEUTICAL SYNTHESIZER MARKET ANALYSIS BY APPLICATION 
FIGURE 124. REST OF MEA RADIOPHARMACEUTICAL SYNTHESIZER MARKET ANALYSIS BY RADIOISOTOPE 
FIGURE 125. REST OF MEA RADIOPHARMACEUTICAL SYNTHESIZER MARKET ANALYSIS BY SYNTHESIS METHOD 
FIGURE 126. REST OF MEA RADIOPHARMACEUTICAL SYNTHESIZER MARKET ANALYSIS BY REGIONAL 
FIGURE 127. KEY BUYING CRITERIA OF RADIOPHARMACEUTICAL SYNTHESIZER MARKET 
FIGURE 128. RESEARCH PROCESS OF MRFR 
FIGURE 129. DRO ANALYSIS OF RADIOPHARMACEUTICAL SYNTHESIZER MARKET 
FIGURE 130. DRIVERS IMPACT ANALYSIS: RADIOPHARMACEUTICAL SYNTHESIZER MARKET 
FIGURE 131. RESTRAINTS IMPACT ANALYSIS: RADIOPHARMACEUTICAL SYNTHESIZER MARKET 
FIGURE 132. SUPPLY / VALUE CHAIN: RADIOPHARMACEUTICAL SYNTHESIZER MARKET 
FIGURE 133. RADIOPHARMACEUTICAL SYNTHESIZER MARKET, BY MODALITY, 2024 (% SHARE) 
FIGURE 134. RADIOPHARMACEUTICAL SYNTHESIZER MARKET, BY MODALITY, 2019 TO 2032 (USD Billions) 
FIGURE 135. RADIOPHARMACEUTICAL SYNTHESIZER MARKET, BY APPLICATION, 2024 (% SHARE) 
FIGURE 136. RADIOPHARMACEUTICAL SYNTHESIZER MARKET, BY APPLICATION, 2019 TO 2032 (USD Billions) 
FIGURE 137. RADIOPHARMACEUTICAL SYNTHESIZER MARKET, BY RADIOISOTOPE, 2024 (% SHARE) 
FIGURE 138. RADIOPHARMACEUTICAL SYNTHESIZER MARKET, BY RADIOISOTOPE, 2019 TO 2032 (USD Billions) 
FIGURE 139. RADIOPHARMACEUTICAL SYNTHESIZER MARKET, BY SYNTHESIS METHOD, 2024 (% SHARE) 
FIGURE 140. RADIOPHARMACEUTICAL SYNTHESIZER MARKET, BY SYNTHESIS METHOD, 2019 TO 2032 (USD Billions) 
FIGURE 141. RADIOPHARMACEUTICAL SYNTHESIZER MARKET, BY REGIONAL, 2024 (% SHARE) 
FIGURE 142. RADIOPHARMACEUTICAL SYNTHESIZER MARKET, BY REGIONAL, 2019 TO 2032 (USD Billions) 
FIGURE 143. BENCHMARKING OF MAJOR COMPETITORS

Download Free Sample

Kindly complete the form below to receive a free sample of this Report

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories
Case Study Cover Image
Case Study
Aerospace & Defense
Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization âś“ âś“ âś“
Direct Access to Analyst âś“ âś“ âś“
Deliverable Format âś“ âś“ âś“
Platform Access âś— âś— âś“
Discount on Next Purchase 10% 15% 15%
Printable Versions âś— âś— âś“